Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 2/2007

01-08-2007

Therapy with Bortezomib plus Dexamethasone Induces Osteoblast Activation in Responsive Patients with Multiple Myeloma

Authors: Shuji Ozaki, Osamu Tanaka, Shiro Fujii, Yuri Shigekiyo, Hirokazu Miki, Masahito Choraku, Kumiko Kagawa, Jin Asano, Kyoko Takeuchi, Ken-ichi Kitazoe, Toshihiro Hashimoto, Masahiro Abe, Toshio Matsumoto

Published in: International Journal of Hematology | Issue 2/2007

Login to get access
Metadata
Title
Therapy with Bortezomib plus Dexamethasone Induces Osteoblast Activation in Responsive Patients with Multiple Myeloma
Authors
Shuji Ozaki
Osamu Tanaka
Shiro Fujii
Yuri Shigekiyo
Hirokazu Miki
Masahito Choraku
Kumiko Kagawa
Jin Asano
Kyoko Takeuchi
Ken-ichi Kitazoe
Toshihiro Hashimoto
Masahiro Abe
Toshio Matsumoto
Publication date
01-08-2007
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 2/2007
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1532/IJH97.07030

Other articles of this Issue 2/2007

International Journal of Hematology 2/2007 Go to the issue

Case Report

t(6;14)(q15;q32) in a Patient with CD5+CD10+ Diffuse Large B-Cell Lymphoma

OriginalPaper

The Gain-of-Function JAK2 V617F Mutation Shifts the Phenotype of Essential Thrombocythemia and Chronic Idiopathic Myelofibrosis to More “Erythremic” and Less “Thrombocythemic”: A Molecular, Histologic, and Clinical Study

Progress in Hematology

Human T-Cell Leukemia Virus Type 1 Tax and Cellular Transformation

Progress in Hematology

Immunologic Control of Human T-Cell Leukemia Virus Type I and Adult T-Cell Leukemia

OriginalPaper

A Prospective Study of Cyclosporine A Treatment of Patients with Low-Risk Myelodysplastic Syndrome: Presence of CD55−CD59− Blood Cells Predicts Platelet Response

OriginalPaper

L-Arginine Administration Reverses Anemia Associated with Renal Disease
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits